Vigil Neuroscience Inc (VIGL)
4.06
-0.42
(-9.38%)
USD |
NASDAQ |
Jun 28, 16:00
4.05
-0.01
(-0.25%)
After-Hours: 07:10
Vigil Neuroscience SG&A Expense (TTM): 28.08M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 28.08M |
December 31, 2023 | 27.93M |
September 30, 2023 | 27.54M |
June 30, 2023 | 25.48M |
March 31, 2023 | 23.41M |
December 31, 2022 | 21.44M |
Date | Value |
---|---|
September 30, 2022 | 18.62M |
June 30, 2022 | 16.70M |
March 31, 2022 | 13.88M |
December 31, 2021 | 10.08M |
September 30, 2021 | 7.103M |
June 30, 2021 | 5.07M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
5.07M
Minimum
Jun 2021
28.08M
Maximum
Mar 2024
18.78M
Average
20.03M
Median
SG&A Expense (TTM) Benchmarks
Assure Holdings Corp | 14.30M |
Tonix Pharmaceuticals Holding Corp | 36.67M |
Savara Inc | 17.94M |
TG Therapeutics Inc | 129.22M |
scPharmaceuticals Inc | 59.92M |